Skip to main content

Allarity Therapeutics, Inc.

corporate_fare Company Profile

Allarity Therapeutics, Inc.

ALLR·NASDAQ·Life Sciences·CIK 0001860657

Allarity is a clinical-stage, precision medicine pharmaceutical company that develops new anti-cancer treatments for patients with significant unmet medical needs. The company's foundation is its proprietary Drug Response Predictor (DRP®) platform. This technology identifies gene expression patterns in cancer cells that indicate how sensitive they are to specific cancer drugs. Once these DRP® gene expression signatures are defined, they can be used to analyze cancer tissue biopsies from patients. This process helps identify cancers that share the drug sensitivity signature, thereby pinpointing patients most likely to benefit from a particular anti-cancer therapeutic. Allarity has developed and published DRP® signatures for dozens of anti-cancer therapeutics. The aim is to use DRP to focus clinical development on smaller, more responsive patient populations, potentially leading to smaller, less expensive, and faster trials, and increasing the likelihood of clinical and regulatory success. Historically, Allarity has created DRP signatures for many anti-cancer therapeutics and in-licensed several assets for DRP-guided development, including Liposomal CisPlatin (LiPlaCis), Irofulven, dovitinib, and the PARP/tankyrase inhibitor, stenoparib. In 2024, Thomas H. Jensen, a co-founder, became Chief Executive Officer, and in 2025, Jeffrey Ervin was hired as Chief Financial Officer.

Allarity Therapeutics, Inc. (NASDAQ:ALLR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ALLR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Allarity Therapeutics Secures $20M in Highly Dilutive Debt Financing with Onerous Terms
  • Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 SCLC Trial
  • Selling Stockholder Registers Resale of 255,103 Shares, Company Receives No Proceeds
  • Allarity Therapeutics Opens Enrollment for New Phase 2 Lung Cancer Trial
  • Allarity Therapeutics Registers $6.0M Equity Line of Credit, Signaling Substantial Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$320K
Net Income
-$11.23M
Op. Cash Flow
-$14.82M
Free Cash Flow
-$14.83M
Operating Income
-$12.61M
Cash & Equivalents
$14.69M
Debt / Equity
0.00×
Net Margin
-35.10×
Shares Outstanding
16.08M sh
Source: 10-K · filed 2026-03-30 · accession 0001437749-26-010310
$0.80 +1.91% today
52-week range · as of 2026-11-17 $0.7687 – $1.84
Market cap
$12.56M
Volume
306.4K (1.9× avg)
3-mo avg 163.7K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALLR - Filings & News (Page 2)

ALLR
Mar 06, 2026, 8:22 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9941
Real-time Price: $0.800 info
Change: -$0.1941 (-20%) info
Market Cap: $12.558M info
ALLR
Feb 19, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.886
Real-time Price: $0.800 info
Change: -$0.086 (-10%) info
Market Cap: $12.558M info
ALLR
Feb 12, 2026, 4:18 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $0.8598
Real-time Price: $0.800 info
Change: -$0.0598 (-7%) info
Market Cap: $12.558M info
ALLR
Feb 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8502
Real-time Price: $0.800 info
Change: -$0.0502 (-6%) info
Market Cap: $12.558M info
ALLR
Jan 29, 2026, 8:00 AM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $0.800 info
Change: -$0.300 (-27%) info
Market Cap: $12.558M info
ALLR
Jan 29, 2026, 7:49 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $0.800 info
Change: -$0.300 (-27%) info
Market Cap: $12.558M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets